Application of Neratinib in Breast Cancer Broadens
Rachel Narozniak, MA
Published: Wednesday, Apr 08, 2020
Adam M. Brufsky, MD, PhD, FACP
The recent approval of neratinib (Nerlynx) in combination with capecitabine (Xeloda) for patients with late-stage, heavily pretreated HER2-positive breast cancer expanded the therapy’s established role in this disease setting.
... to read the full story